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We describe clinical characteristics, treatments and 
outcomes of 44 Caucasian patients with coronavirus 
disease (COVID-19) at a single hospital in Pavia, Italy, 
from 21–28 February 2020, at the beginning of the 
outbreak in Europe. Seventeen patients developed 
severe disease, two died. After a median of 6 days, 14 
patients were discharged from hospital. Predictors of 
lower odds of discharge were age > 65 years, antiviral 
treatment and for severe disease, lactate dehydroge-
nase > 300 mg/dL.
Severe acute respiratory syndrome coronavirus-2 
(SARS-CoV-2) is an emerging virus recently detected 
and associated with a severe respiratory disease, 
named coronavirus disease (COVID-19), which has 
been declared a pandemic disease by the World Health 
Organization (WHO) on 11 March 2020 [1].
As at 20 April 2020, 1,149,071 confirmed cases of 
COVID 19 were reported in Europe, of which 181,228 
were in Italy [2].
To date, while there are numerous studies describing 
clinical characteristics of COVID-19 patients from China 
[3-6], there are only few published from European coun-
tries. Here we report early findings on clinical presen-
tation, treatment and clinical outcomes of patients 
with COVID-19 in a large teaching hospital in Pavia, 
Lombardy region, northern Italy, as well as preliminary 
analyses of predictors of discharge status and of devel-
oping severe disease.
Data extraction and analysis
We extracted data from medical records of all consecu-
tive patients admitted with a diagnosis of COVID-19, 
between 21 and 28 February 2020 and followed-up 
until 4 March 2020. We collected demographic data 
(sex and age), clinical data (symptoms on admission, 
comorbidities and chest X-ray results), laboratory tests 
and treatment data (use of antivirals, antibiotic drugs 
and oxygen support). Diagnosis of COVID-19 was con-
firmed by positive real-time reverse transcriptase PCR 
from nasal swabs, which were analysed by the molecu-
lar virology unit of our hospital according to the WHO 
guidelines and protocol by Corman et al. [7].
Severe disease was defined as requirement for high-
flow oxygen support. Low (cannula and simple masks) 
and high-flow (Venturi and reservoir masks) oxy-
gen support were provided when hypoxia defined as 
peripheral oxygen saturation < 90% was detected.
Univariate logistic analysis was employed to iden-
tify variables associated with hospital discharge and 
development of severe disease. The multivariable 
model was built to determine the association between 
the variables which threshold values were <0.10 at uni-
variate analysis. In this final model, variables with a p 
value < 0.05 were considered statistically significant.
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Table 1
Clinical characteristics, imaging results and laboratory findings of patients with laboratory-confirmed COVID-19 by disease 
severity and discharge status, Pavia, northern Italy, 21–28 February 2020 (n = 44)a
Total sample
Stratified by disease 
severityb Stratified by discharge status
b
Mild disease 
 
(n = 27)
Severe 
disease 
 
(n = 17)
Not discharged 
 
(n = 30)
Discharged 
 
(n = 14)
n n n n n
Sex (F) 16 12 4 9 7
Age > 65 years 25 12 13 22 3
Clinical manifestation
Respiratory frequency > 22/min 16 7 9 14 2
Fever (Body Temperature > 37.5°C) 40 23 17 30 10
Cough 15 10 5 13 2
Dyspnoea 10 6 4 8 2
Diarrhoea 3 1 2 2 1
Weakness 2 2 0 5 1
Chest X-ray
Interstitial pneumonia 31 17 14 26 5
Comorbidities
Presence of comorbidities 28 15 13 24 4
Cancer 6 2 4 5 1
Heart disease 11 5 6 8 3
Hypertension 15 10 5 14 1
Diabetes mellitus 7 6 1 6 1
Lung disease 2 2 0 1 1
Chronic hepatitis C 2 1 1 1 1
Laboratory data
PF ratio < 260 (n = 25) 10 2 8 10 0
CO2 < 35 (n = 25) 16 10 6 16 0
pH < 7.45 (n = 25) 7 5 2 7 0
Leukopenia (white blood cell count < 5,000 cells/mm3) 22 13 9 17 5
Lymphopenia (lymphocyte count <1,500 cells/mm3) 39 22 17 29 10
Thrombocytopenia (platelets <150,000/ mm3) 19 9 10 15 4
CD4+ T-cell count < 250 cells/μL 14 8 6 10 4
LDH > 300 mU/mL 15 5 10 13 2
Creatinine > 1.5 mg/dL 2 0 2 2 0
CRP elevation (CRP > 10 mg/dL) 8 3 5 8 0
25 ng/mL 8 3 5 8 0
Therapy
Antiviral therapyc 31 14 17 27 4
Antibiotic therapyd 32 17 15 27 5
CO: carbon dioxide; CRP: C-reactive protein; F: female; LDH: lactate dehydrogenase; PCTI: procalcitonin; PF ratio: arterial partial pressure of 
oxygen/fractional inspired oxygen.
a Follow up as at 4 March 2020.
b Patients were included in the mild disease group if they did not need high-flow oxygen support and in the severe disease group if they were 
provided with high-flow oxygen support.
c Lopinavir/ritonavir (LPV/r) 200/50 mg twice a day plus hydroxychloroquine 200 mg twice a day.
d Piperacillin/tazobactam and doxycycline.
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Clinical characteristics
From 21 February to 28 February 2020, 44 confirmed 
cases of COVID-19 were observed. The majority were 
males (28 males, 16 females). Median age was 67.5 
years (range: 10–94 years, interquartile range (IQR): 
29.1) and 19 patients were under 65 years old. Clinical 
signs on admission were fever (n = 40), cough (n = 15 ), 
dyspnoea (n = 10), diarrhoea (n = 3), weakness (n = 2); 
confusion, respiratory failure, constipation, chest pain 
and muscle pain were each reported by one patient 
(Table 1).
Remarkably, 16 patients had no underlying comorbidi-
ties. The most common comorbidities were hyperten-
sion (n = 15), heart disease (n = 11), diabetes mellitus 
(n  =  7), history of cancer (n  =  6; five solid carcino-
mas, one B-cell lymphoma), lung diseases (n = 2) and 
chronic hepatitis C (n = 2). Only one patient had chronic 
kidney disease. We observed no cases with known 
immunodeficiency, either congenital or acquired. Chest 
X-ray revealed the presence of 31 cases of interstitial 
pneumonia (n = 31). Table 1 shows laboratory findings 
on admission. Lymphocytopenia was present in 39 
patients, thrombocytopenia was observed in 19, and 
leukopenia in 22. CD4+ T-cell count was < 250 cells/μL 
in 14 patients. LDH levels were elevated in 15.
Twenty-five patients with hypoxia underwent an arte-
rial-blood gas test. Assuming a normal arterial oxygen 
partial pressure to fractional inspired oxygen (PaO2/
FiO2 or P/F) ratio in the remaining 19 patients, a P/F 
ratio less than 260 was found in 10 patients.
Thirteen patients did not receive any antiviral drug, 
while 31 patients received antiviral treatment (Table 
1). Antiviral treatment consisted in lopinavir/ritonavir 
(LPV/r) 200/50 mg twice a day plus hydroxychloro-
quine (HCQ) 200 mg twice a day. Antibiotic therapy 
was started in 32 patients and consisted of piperacil-
lin/tazobactam and doxycycline. Supportive therapy 
was delivered based on clinical indications.
Factors associated with clinical outcome
In the univariate analysis for discharge, age > 65 years, 
interstitial pneumonia, presence of comorbidities, 
hypertension and antibiotic therapy were significantly 
associated with lower odds of discharge. In the univari-
ate analysis for disease severity, male sex, respiratory 
frequency > 22, cancer as comorbidity, thrombocytope-
nia and arterial partial pressure of oxygen/fractional 
inspired oxygen (PF) ratio <  260 were significantly 
associated with higher odds for severe disease.
LDH levels >  300 mU/mL and antiviral therapy were 
associated with both outcomes (Supplementary mate-
rial, Table S1).
As at 4 March 2020, 14 patients were discharged from 
the hospital. In these patients, median time from 
symptom onset was 12 days (range: 6–30 days, IQR: 
6) and median time of hospitalisation was 6 days 
(range: 4–7 days, IQR: 2). Age over 65 years and antivi-
ral treatment were significantly associated with lower 
odds of discharge, by multivariable analysis (Table 2). 
Seventeen patients had severe disease and there were 
two fatalities. LDH levels >  300 mU/mL were signifi-
cantly associated with higher odds of severe disease, 
by multivariable analysis (Table 2).
In the  supplementary materials  we report detailed 
results of univariate and multivariable analysis. 
Particularly,  Table S2  show results of model 
for discharge status, and  Table S3  for severe 
disease.  Table S4  reports the characteristics of 
patients who have received and who have not 
received antiviral treatment.  Table S5  reports model 
for antiviral treatment. Eventually, Table S6 shows the 
characteristics of patients according to LDH levels.
Two patients received sub-intensive care. In these 
patients, time from symptom onset was 10 and 13 
days, respectively and time from hospitalisation was 
5 days. Three patients were admitted to the intensive 
care unit. Time from symptom onset in these patients 
was 10, 12, 25 days, respectively and time from hospi-
talisation was 4 days in two and 5 days in one patient. 
The deaths occurred 9 and 10 days, respectively, after 
the onset of symptoms and 3 days after hospitalisa-
tion. As at 4 March, 23 patients were still in the isola-
tion room receiving standard care, including standard 
supportive care.
No bacterial infections were observed during the first 
week of observation. Two patients without known renal 
disease, developed kidney failure during hospital stay.
 
Discussion and conclusions
Our early experiences from the COVID-19 pandemic 
showed significant morbidity in an aged population 
with high prevalence of coexisting illnesses. Older 
age and antiviral treatment were significantly associ-
ated with lower odds of hospital discharge; LDH levels 
Table 2
Multivariable logistic regression of factors influencing 
outcome of laboratory-confirmed COVID-19 cases, Pavia, 
northern Italy, 21–28 February 2020 (n = 44)
Outcomea OR 95% CI p value
Lower probability of discharge from hospital
Age > 65 years 0.043 0.004–0.504 0.012
Antiviral treatment 0.048 0.006–0.399 0.005
Severe diseaseb
LDH level 1.090 1.022–1.163 0.008
CI: confidence interval; LDH: lactate dehydrogenase; OR: odd 
ratios.
a Follow up as at 4 March 2020.
b Patients were included in the mild disease group if they did not 
need high-flow oxygen support and in the severe disease group 
if they were provided with high-flow oxygen support.
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> 300mg/dL were associated with higher odds of devel-
oping severe disease.
It is important to underline that the median age and 
prevalence of coexisting illnesses observed in our 
cohort were higher than those reported in studies from 
China [8,9], potentially leading to a more severe clini-
cal course. Similar to other studies, the most common 
comorbidities were hypertension, chronic heart dis-
ease and diabetes mellitus [10].
A high number of our patients received antiviral treat-
ment with LPV/r plus HCQ. However, patients who 
received antiviral treatment had lower odds of dis-
charge. This association appears plausible because 
of the propensity of physicians to administer antivi-
ral treatment to patients with more severe disease. 
The actual role of therapy, and the optimal treatment 
schedule for COVID-19 are still unclear. Doubts were 
raised regarding the clinical effectiveness of LPV/r [11] 
and several clinical trials are underway to evaluate the 
efficacy of other novel antivirals (e.g. remdesivir) and 
selective cytokine blockade (e.g. tocilizumab) [12].
Based on findings in the literature, most of our patients 
received antibiotic combination therapy, to cover both 
common and atypical pathogens [8]. Remarkably, no 
bacterial superinfections were observed during the 
first week of observation.
It is interesting to underline that among biological 
markers, heightened LDH levels were the only inde-
pendent risk factors for severe disease. This finding 
was also reported in previous Chinese studies [8,13,14] 
as well as in an earlier study on Middle East respira-
tory syndrome (MERS) coronavirus [15]. It is well known 
that elevated LDH levels are suggestive of haema-
tological malignancy and acute lung injury, such as 
Pneumocystis pneumonia (PCP) in HIV patients [16]. 
LDH levels might reflect tissue necrosis related to 
immune hyperactivity and thus relate to poor clinical 
outcome [17]. LDH levels may be a useful and easy to 
test parameter in order to identify patients at risk for 
severe respiratory failure.
The lymphocyte count is a parameter that has been 
described as linked to prognosis of COVID-19. Our lab-
oratory data showed a low lymphocyte count in a con-
siderable proportion of patients, a finding confirming 
previous reports [18-20]. Our results support the use of 
low absolute value of lymphocyte counts as a reference 
index in the diagnosis of COVID-19 [8,21].
Regarding the clinical characteristics of our cohort, 
fever was the most common symptom, this is similar to 
the results reported by a meta-analysis of studies per-
formed in Chinese patients [22]. However, both cough 
and muscle weakness/fatigue were less frequent than 
in other studies. Although some studies demonstrated 
the presence of SARS-CoV-2 in stool samples [23] 
and that it might be associated with gastrointestinal 
symptoms [24], nausea and diarrhoea were rare in our 
patients. Further studies are needed to assess if these 
differences reflect peculiar clinical manifestation of the 
disease in the Italian context.
To date, more than 700 COVID-19 patients have been 
admitted to our hospital and further, more in-depth 
studies will follow. However, this picture of the first 
week of COVID-19 outbreak provides information 
regarding the disease outside China in a real life-set-
ting of a country with very high case numbers. Although 
our study is limited by the small number of patients 
and by the short follow-up, our findings suggest that 
in a Caucasian aged population with high prevalence 
of coexisting illnesses, COVID-19 is characterised by 
notable morbidity.
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